Understanding GLP-1 Medications: Semaglutide, Tirzepatide & How They Work

What Are GLP-1 Medications?

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of prescription medications that mimic or amplify the action of GLP-1 — a gut hormone naturally secreted after eating that signals satiety, slows digestion, and regulates appetite. In people with obesity, GLP-1 signaling is chronically blunted, creating persistent hunger regardless of caloric intake. GLP-1 receptor agonists restore this signaling pharmacologically, addressing the biological root of obesity rather than asking patients to override their biology with willpower.

The most relevant GLP-1 medications available through Tmates telehealth are compounded semaglutide ($249/mo) and compounded tirzepatide ($297/mo) — both the most clinically studied and most effective pharmacological weight loss options currently available. The FDA-approved branded versions (Wegovy® and Zepbound®) use the same active molecules at equivalent doses; Tmates also provides prescription management services for brand-name Wegovy® ($99/mo) and Zepbound® ($99/mo) for patients who specifically want FDA-approved products.

How GLP-1 Medications Produce Weight Loss

Three primary mechanisms drive GLP-1-mediated weight loss. First, hypothalamic appetite suppression: GLP-1 receptors in the hypothalamus regulate hunger signaling. When activated at therapeutic levels by semaglutide or tirzepatide, these receptors reduce the persistent hunger drive that makes caloric restriction feel like constant struggle. Second, slowed gastric emptying: GLP-1 slows the rate at which the stomach empties food into the small intestine — food stays in the stomach longer, extending the feeling of fullness after meals. Third, food noise elimination: perhaps the most clinically important and least discussed mechanism — the constant mental preoccupation with eating, cravings, and food that patients with obesity describe as exhausting background noise. GLP-1 medications normalize this experience, making appropriate portions feel natural rather than effortful.

Tirzepatide adds a second receptor target: GIP (glucose-dependent insulinotropic polypeptide) receptor agonism, which improves peripheral insulin sensitivity and fat metabolism beyond what GLP-1 alone produces. This is why SURMOUNT-1 documented 22.5% average weight loss versus STEP-1's 14.9% — two synchronized receptor mechanisms versus one. See the complete semaglutide vs tirzepatide comparison.

Who Qualifies for GLP-1 Medications?

Clinical eligibility criteria: BMI ≥30 (obese), or BMI ≥27 (overweight) with at least one weight-related health condition (type 2 diabetes, hypertension, high cholesterol, sleep apnea, cardiovascular disease, prediabetes, PCOS). Absolute contraindications include personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2), current pregnancy or intention to become pregnant within 6 months, active pancreatitis, and known hypersensitivity to semaglutide or tirzepatide. Your Tmates physician reviews your complete health history during intake to confirm eligibility and check for contraindications.

Condition-specific guides: GLP-1 for obesity, GLP-1 for PCOS, GLP-1 for prediabetes, GLP-1 for metabolic syndrome. See the weight loss journey guide for patient timeline expectations. Compare platforms: Tmates vs Medvi, Tmates vs TrimRx. Read the comprehensive Tmates review 2026 for full platform analysis. Explore the weight loss category and how Tmates works.